Psychiatric News (7/5) reports, “Psychedelics such as 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin have shown promise for the treatment of such psychiatric disorders as posttraumatic stress disorder and depression,” but “any FDA approval of psychedelics will almost certainly lead to substantial off-label use as well, cautioned medical ethicists in a Viewpoint piece” published online June 29 in JAMA Psychiatry.
Related Links:
— “Guardrails Needed to Control Promotion, Off-label Use of Psychedelics, Psychiatric News, July 5, 2022